{"id":9665,"date":"2026-03-18T11:12:29","date_gmt":"2026-03-18T03:12:29","guid":{"rendered":"https:\/\/regask.com\/?p=9665"},"modified":"2026-03-18T11:12:29","modified_gmt":"2026-03-18T03:12:29","slug":"la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","title":{"rendered":"La EMA abre el plazo de solicitud para el programa de cartera y tecnolog\u00eda de 2026\u2026"},"content":{"rendered":"<p><span data-contrast=\"auto\">En\u00a0<\/span><b><span data-contrast=\"auto\">10 de marzo de 2026<\/span><\/b><span data-contrast=\"auto\">, el\u00a0<\/span><b><span data-contrast=\"auto\">Agencia Europea de Medicamentos (EMA)<\/span><\/b><span data-contrast=\"auto\">\u00a0anunci\u00f3 que las solicitudes ya est\u00e1n abiertas para\u00a0<\/span><b><span data-contrast=\"auto\">Reuniones de cartera y tecnolog\u00eda (PTM)<\/span><\/b><span data-contrast=\"auto\">\u00a0programado para el\u00a0<\/span><b><span data-contrast=\"auto\">segunda mitad de 2026<\/span><\/b><span data-contrast=\"auto\">. El programa invita\u00a0<\/span><b><span data-contrast=\"auto\">Grandes compa\u00f1\u00edas farmac\u00e9uticas con amplias carteras de productos medicinales.<\/span><\/b><span data-contrast=\"auto\">\u00a0entablar conversaciones estructuradas con la agencia.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Estos\u00a0<\/span><b><span data-contrast=\"auto\">reuniones virtuales gratuitas<\/span><\/b><span data-contrast=\"auto\">\u00a0est\u00e1n dise\u00f1ados para abordar\u00a0<\/span><b><span data-contrast=\"auto\">desaf\u00edos en el desarrollo de la cartera de productos<\/span><\/b><span data-contrast=\"auto\">, captura\u00a0<\/span><b><span data-contrast=\"auto\">tecnolog\u00edas emergentes y disruptivas<\/span><\/b><span data-contrast=\"auto\">, y ayudar a la EMA a anticipar la\u00a0<\/span><b><span data-contrast=\"auto\">Se requieren conocimientos cient\u00edficos y regulatorios para futuras solicitudes de autorizaci\u00f3n de comercializaci\u00f3n.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Las empresas interesadas en participar deben presentar la informaci\u00f3n designada.\u00a0<\/span><b><span data-contrast=\"auto\">Formulario de solicitud PTM antes del 30 de abril de 2026.<\/span><\/b><span data-contrast=\"auto\">.La EMA revisar\u00e1 las solicitudes y notificar\u00e1 a los solicitantes el resultado.\u00a0<\/span><b><span data-contrast=\"auto\">para finales de mayo de 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><\/p>\n<div class=\"row\"  id=\"row-624610045\">\n\n\t<div id=\"col-338429152\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-1055434618\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1055434618 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>Detalles de la actualizaci\u00f3n<\/h2>\n\t<div id=\"gap-180517511\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-180517511 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">Reuniones de cartera y tecnolog\u00eda (PTM)<\/span><\/b><span data-contrast=\"auto\">\u00a0brindar una oportunidad para que las grandes compa\u00f1\u00edas farmac\u00e9uticas discutan\u00a0<\/span><b><span data-contrast=\"auto\">Consideraciones regulatorias y cient\u00edficas para toda la cartera de productos.<\/span><\/b><span data-contrast=\"auto\">\u00a0directamente con la EMA. Las reuniones se llevan a cabo\u00a0<\/span><b><span data-contrast=\"auto\">virtualmente y sin costo para los solicitantes<\/span><\/b><span data-contrast=\"auto\">, reduciendo las barreras a la participaci\u00f3n y facilitando al mismo tiempo el compromiso estrat\u00e9gico.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">El programa est\u00e1 dise\u00f1ado espec\u00edficamente para ayudar a identificar\u00a0<\/span><b><span data-contrast=\"auto\">problemas que afectan al progreso de la cartera de productos<\/span><\/b><span data-contrast=\"auto\">\u00a0y facilitar el di\u00e1logo sobre\u00a0<\/span><b><span data-contrast=\"auto\">tecnolog\u00edas innovadoras y disruptivas<\/span><\/b><span data-contrast=\"auto\">\u00a0que pueden influir en futuras evaluaciones regulatorias. A trav\u00e9s de estas discusiones, la EMA pretende alinear sus\u00a0<\/span><b><span data-contrast=\"auto\">competencias cient\u00edficas y regulatorias<\/span><\/b><span data-contrast=\"auto\">\u00a0con las necesidades cambiantes de los oleoductos de la industria.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Si se concede una solicitud de reuni\u00f3n, los solicitantes deben presentar un\u00a0<\/span><b><span data-contrast=\"auto\">documento informativo completo<\/span><\/b><span data-contrast=\"auto\">\u00a0utilizando el\u00a0<\/span><b><span data-contrast=\"auto\">Plantilla proporcionada por la EMA (N\u00famero de referencia: EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">. Este documento debe ser entregado\u00a0<\/span><b><span data-contrast=\"auto\">De cuatro a seis semanas antes de la reuni\u00f3n programada a trav\u00e9s de Eudralink.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Adem\u00e1s, los solicitantes deben presentar un\u00a0<\/span><b><span data-contrast=\"auto\">Presentaci\u00f3n previa a la reuni\u00f3n y lista de participantes una semana antes de la fecha de la reuni\u00f3n.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-338429152 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1011485530\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Fecha l\u00edmite para comentarios<\/h2>\n\t<div id=\"gap-221781930\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-221781930 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">La fecha l\u00edmite para presentar el formulario de solicitud para la Reuni\u00f3n de Portafolio y Tecnolog\u00eda es el 30 de abril de 2026.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">La Agencia Europea de Medicamentos comunicar\u00e1 los resultados de las solicitudes y los pr\u00f3ximos pasos a finales de mayo de 2026.<\/span><\/b><span data-contrast=\"auto\">, con reuniones aprobadas programadas para tener lugar durante el\u00a0<\/span><b><span data-contrast=\"auto\">segunda mitad de 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1011485530 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-702400002\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Por qu\u00e9 es importante<\/h2>\n\t<div id=\"gap-713191469\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-713191469 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">El\u00a0<\/span><b><span data-contrast=\"auto\">Programa PTM<\/span><\/b><span data-contrast=\"auto\">\u00a0ofrece una oportunidad estructurada para empresas con\u00a0<\/span><b><span data-contrast=\"auto\">grandes carteras de productos medicinales<\/span><\/b><span data-contrast=\"auto\">\u00a0abordar\u00a0<\/span><b><span data-contrast=\"auto\">desaf\u00edos del desarrollo interdepartamental y tecnolog\u00edas emergentes<\/span><\/b><span data-contrast=\"auto\">\u00a0con los reguladores en una etapa temprana.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Al permitir un di\u00e1logo temprano, la iniciativa apoya\u00a0<\/span><b><span data-contrast=\"auto\">estrategia regulatoria proactiva<\/span><\/b><span data-contrast=\"auto\">, mejora\u00a0<\/span><b><span data-contrast=\"auto\">alineaci\u00f3n en las expectativas cient\u00edficas<\/span><\/b><span data-contrast=\"auto\">, y ayuda a reducir\u00a0<\/span><b><span data-contrast=\"auto\">incertidumbre regulatoria futura<\/span><\/b><span data-contrast=\"auto\">\u00a0en carteras complejas, incluyendo\u00a0<\/span><b><span data-contrast=\"auto\">nuevas modalidades, productos biol\u00f3gicos y terapias avanzadas<\/span><\/b><span data-contrast=\"auto\">. El\u00a0<\/span><b><span data-contrast=\"auto\">formato virtual y gratuito<\/span><\/b><span data-contrast=\"auto\">\u00a0Mejora a\u00fan m\u00e1s la accesibilidad para las organizaciones que cumplen los requisitos.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-702400002 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1394076497\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Para qui\u00e9n es relevante<\/h2>\n\t<div id=\"gap-1109389499\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1109389499 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Este anuncio es particularmente relevante para <strong>Equipos de Asuntos Regulatorios, Asuntos M\u00e9dicos, Investigaci\u00f3n y Desarrollo y Comerciales<\/strong> dentro de las compa\u00f1\u00edas farmac\u00e9uticas gestionando <strong>amplias carteras de productos medicinales<\/strong>. Estas funciones desempe\u00f1an un papel fundamental en la preparaci\u00f3n de las solicitudes de PTM, la identificaci\u00f3n de problemas que afectan a toda la cartera de productos y la coordinaci\u00f3n de los materiales informativos que abordan las consideraciones cient\u00edficas, regulatorias y estrat\u00e9gicas de la cartera de productos.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1394076497 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-374124450\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Pr\u00f3ximos pasos<\/h2>\n\t<div id=\"gap-1851703103\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1851703103 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Las organizaciones que planean participar deben iniciar la coordinaci\u00f3n interna con anticipaci\u00f3n para garantizar la preparaci\u00f3n y presentaci\u00f3n oportunas de la documentaci\u00f3n.\u00a0<\/span><b><span data-contrast=\"auto\">Formulario de solicitud para la Reuni\u00f3n de Portafolio y Tecnolog\u00eda (PTM) antes del 30 de abril de 2026.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos de Asuntos Regulatorios<\/span><\/b><span data-contrast=\"auto\">\u00a0primero debe evaluar\u00a0<\/span><b><span data-contrast=\"auto\">elegibilidad de la cartera<\/span><\/b><span data-contrast=\"auto\">, complete y env\u00ede el\u00a0<\/span><b><span data-contrast=\"auto\">Aplicaci\u00f3n PTM<\/span><\/b><span data-contrast=\"auto\">, y, si se aprueba la solicitud de reuni\u00f3n, coordinar la preparaci\u00f3n de la\u00a0<\/span><b><span data-contrast=\"auto\">Documento informativo de la EMA (EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">\u00a0y gestionar el\u00a0<\/span><b><span data-contrast=\"auto\">Enviar la informaci\u00f3n a trav\u00e9s de Eudralink entre cuatro y seis semanas antes de la reuni\u00f3n programada.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos de Asuntos M\u00e9dicos<\/span><\/b><span data-contrast=\"auto\">\u00a0deber\u00eda identificar\u00a0<\/span><b><span data-contrast=\"auto\">cuestiones cient\u00edficas y de desarrollo que abarcan toda la cartera de proyectos<\/span><\/b><span data-contrast=\"auto\">\u00a0que puede requerir debate regulatorio y trabajar en estrecha colaboraci\u00f3n con Asuntos Regulatorios para dar forma a la\u00a0<\/span><b><span data-contrast=\"auto\">Agenda de la reuni\u00f3n y aportaciones para la sesi\u00f3n informativa<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos de Investigaci\u00f3n y Desarrollo<\/span><\/b><span data-contrast=\"auto\">\u00a0deber\u00eda contribuir\u00a0<\/span><b><span data-contrast=\"auto\">para canalizar datos y temas relacionados con la tecnolog\u00eda<\/span><\/b><span data-contrast=\"auto\">, incluido\u00a0<\/span><b><span data-contrast=\"auto\">modalidades novedosas o disruptivas<\/span><\/b><span data-contrast=\"auto\">, para su inclusi\u00f3n en el\u00a0<\/span><b><span data-contrast=\"auto\">Documento informativo y presentaci\u00f3n previa a la reuni\u00f3n<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"4\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Equipos comerciales y de marketing<\/span><\/b><span data-contrast=\"auto\">\u00a0deber\u00eda aportar informaci\u00f3n sobre\u00a0<\/span><b><span data-contrast=\"auto\">Prioridades de la estrategia de cartera y la gesti\u00f3n del ciclo de vida<\/span><\/b><span data-contrast=\"auto\">\u00a0que pueden beneficiarse de\u00a0<\/span><b><span data-contrast=\"auto\">alineaci\u00f3n cient\u00edfica temprana con la Agencia Europea de Medicamentos<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><b><span data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/es\/\">RegASK<\/a>\u00a0es una plataforma l\u00edder de inteligencia regulatoria y orquestaci\u00f3n de flujos de trabajo con inteligencia artificial de agencia.<\/span><\/b><span data-contrast=\"auto\">\u00a0que empodera a las organizaciones globales en sectores altamente regulados, incluyendo productos de consumo y ciencias de la vida, para navegar proactivamente en entornos regulatorios complejos. Al combinar\u00a0<\/span><b><span data-contrast=\"auto\">IA avanzada de Agentic con expertos en el circuito<\/span><\/b><span data-contrast=\"auto\">,\u00a0<a href=\"http:\/\/regask.com\/es\/\">RegASK<\/a>\u00a0entrega\u00a0<\/span><b><span data-contrast=\"auto\">Informaci\u00f3n predictiva y procesable oportuna y automatizaci\u00f3n de extremo a extremo<\/span><\/b><span data-contrast=\"auto\">, ayudando a los equipos a realizar un seguimiento de las iniciativas regulatorias, como los programas de colaboraci\u00f3n de la EMA, preparar la documentaci\u00f3n de manera eficiente y optimizar el cumplimiento en m\u00e1s de\u00a0<\/span><b><span data-contrast=\"auto\">160 pa\u00edses<\/span><\/b><span data-contrast=\"auto\">. <a href=\"http:\/\/regask.com\/es\/\"><strong>M\u00e1s informaci\u00f3n <\/strong><\/a>o<a href=\"https:\/\/regask.com\/es\/reservar-una-demostracion\/\"><strong> Reserve una demostraci\u00f3n ahora.<\/strong><\/a><\/span><strong>\u00a0<\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-374124450 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-263829792\">\n\n\t<div id=\"col-1685956531\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>Preguntas frecuentes<\/h3>\n\t<div id=\"gap-1326770515\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1326770515 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4><span class=\"TextRun MacChromeBold SCXW267956491 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW267956491 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfCu\u00e1les son las nuevas directrices del CDE sobre los ensayos cl\u00ednicos de la vacuna contra la gripe?<\/span><\/span><span class=\"EOP SCXW267956491 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1106966355\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1106966355 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong>Reuniones de cartera y tecnolog\u00eda (PTM)<\/strong> son reuniones virtuales estructuradas organizadas por el <strong>Agencia Europea de Medicamentos<\/strong> para permitir que las grandes compa\u00f1\u00edas farmac\u00e9uticas discutan <strong>Desaf\u00edos en el desarrollo de la cartera de productos y tecnolog\u00edas emergentes<\/strong> con el regulador.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1685956531 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1872171286\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW184197477 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW184197477 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfQui\u00e9nes pueden solicitar participar en las reuniones de EMA sobre cartera de proyectos y tecnolog\u00eda?<\/span><\/span><span class=\"EOP SCXW184197477 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1856873698\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1856873698 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>El programa PTM est\u00e1 abierto a <strong>Grandes compa\u00f1\u00edas farmac\u00e9uticas con amplias carteras de productos medicinales.<\/strong> Las empresas que cumplan los requisitos deber\u00e1n presentar un formulario de solicitud a la EMA para su revisi\u00f3n.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1872171286 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-24211678\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW3460145 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW3460145 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfCu\u00e1l es el plazo para solicitar una beca PTM en 2026?<\/span><\/span><span class=\"EOP SCXW3460145 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1465975099\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1465975099 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>El <strong>La fecha l\u00edmite para presentar la solicitud es el 30 de abril de 2026.<\/strong> El <strong>La EMA comunicar\u00e1 los resultados de las solicitudes a finales de mayo de 2026.,<\/strong> y las reuniones aprobadas tendr\u00e1n lugar en el <strong>segunda mitad de 2026. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-24211678 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1399730609\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW14904628 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">\u00bfC\u00f3mo puedo?\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">RegASK<\/span><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">\u00a0\u00bfC\u00f3mo ayudan las organizaciones a gestionar actualizaciones como esta?<\/span><\/span><span class=\"EOP SCXW14904628 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1257574634\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1257574634 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/es\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW253285960 BCX0\">RegASK<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0<strong>Plataforma de inteligencia regulatoria basada en IA con agentes<\/strong><\/span><\/span><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">ayuda a las compa\u00f1\u00edas farmac\u00e9uticas\u00a0<\/span><\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">monitor<\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">Anuncios regulatorios globales, oportunidades de participaci\u00f3n y programas de consulta.<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0en tiempo real. Esto permite a los equipos reguladores\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">identificar<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0iniciativas como\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">Reuniones sobre la cartera de productos y la tecnolog\u00eda de la EMA<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\"><strong>,<\/strong> coordinar la preparaci\u00f3n interna y\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">mantener<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0Preparaci\u00f3n para el cumplimiento normativo en oleoductos globales complejos.<\/span><\/span><span class=\"EOP SCXW253285960 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1399730609 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On\u00a0March 10, 2026, the\u00a0European Medicines Agency (EMA)\u00a0announced that applications are now open for\u00a0Portfolio and Technology Meetings (PTMs)\u00a0scheduled for the\u00a0second half of 2026. The program invites\u00a0large pharmaceutical companies with extensive medicinal product portfolios\u00a0to engage in structured discussions with the agency.\u00a0 These\u00a0virtual, free-of-charge meetings\u00a0are designed to address\u00a0product portfolio development challenges, capture\u00a0emerging and disruptive technologies, and help the&#8230;<\/p>","protected":false},"author":41,"featured_media":9666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,538,35],"tags":[],"class_list":["post-9665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-european-union","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EMA Opens Applications for 2026 Portfolio Meetings<\/title>\n<meta name=\"description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies\" \/>\n<meta property=\"og:description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T03:12:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\"},\"headline\":\"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"wordCount\":1002,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"articleSection\":[\"Regulatory News\",\"European Union\",\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"name\":\"EMA Opens Applications for 2026 Portfolio Meetings\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"description\":\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"width\":800,\"height\":600,\"caption\":\"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"Empowering Smarter Regulatory Decisions\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\",\"name\":\"RegASK\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/RegASK-Logo-Dark-Round.png\",\"width\":401,\"height\":401,\"caption\":\"RegASK\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RegASKRegulatoryAffairs\\\/\",\"https:\\\/\\\/x.com\\\/ASKRegASK\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/RegASK\\\/\",\"https:\\\/\\\/www.youtube.com\\\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/b0e1938ef6f244f9f052a21f21cba1b6\",\"name\":\"Shaffa Renaningtyas\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La EMA abre el plazo de solicitud para las reuniones de cartera de 2026.","description":"La EMA abre el plazo de solicitud para las Reuniones de Cartera y Tecnolog\u00eda de 2026 dirigidas a grandes empresas farmac\u00e9uticas. El plazo de solicitud finaliza el 30 de abril.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/","og_locale":"es_ES","og_type":"article","og_title":"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies","og_description":"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.","og_url":"https:\/\/regask.com\/es\/la-ema-abre-el-plazo-de-solicitud-para-las-reuniones-de-cartera-y-tecnologia-de-2026-dirigidas-a-grandes-empresas-farmaceuticas\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-03-18T03:12:29+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#article","isPartOf":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6"},"headline":"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;","datePublished":"2026-03-18T03:12:29+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"wordCount":1002,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","articleSection":["Regulatory News","European Union","Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","url":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","name":"La EMA abre el plazo de solicitud para las reuniones de cartera de 2026.","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","datePublished":"2026-03-18T03:12:29+00:00","description":"La EMA abre el plazo de solicitud para las Reuniones de Cartera y Tecnolog\u00eda de 2026 dirigidas a grandes empresas farmac\u00e9uticas. El plazo de solicitud finaliza el 30 de abril.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","width":800,"height":600,"caption":"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Habilitando decisiones regulatorias m\u00e1s inteligentes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/regask.com\/#organization","name":"RegASK","url":"https:\/\/regask.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/10\/RegASK-Logo-Dark-Round.png","width":401,"height":401,"caption":"RegASK"},"image":{"@id":"https:\/\/regask.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","https:\/\/x.com\/ASKRegASK","https:\/\/www.linkedin.com\/company\/RegASK\/","https:\/\/www.youtube.com\/playlist?list=PL6yPC6gFqelkHbOeyUVKjtHOZXZ2LQbJd"]},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/b0e1938ef6f244f9f052a21f21cba1b6","name":"Shaffa Renaningtyas"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=9665"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/9665\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/9666"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=9665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=9665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=9665"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}